Abstract: The present invention is related to compositions comprising decellularized cartilage tissue powder in the forms of paste, putty, hydrogel, and scaffolds, methods of making compositions, and methods of using these compositions for treating osteochondral defects and full- or partial-thickness cartilage defects.

Abstract: Disclosed herein are sprayable compositions comprising: a complex of (A) at least one charged (or pseudo-charged) polymer having a molecular weight of about 125,000 amu or more; and (B) a least one oppositely charged, rheology modifying, crosslinked polymer having at least one carboxylic functional group. The composition may provide a spray with a median particle size of less than about 175 ?m. Also disclosed are methods for preparing the compositions as well as creating the spray. The invention enables the spray of the high molecular weight charged (or pseudo-charged) polymer in any number of uses including personal care and performance chemicals application.

Abstract: Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

Abstract: A drug carrier, a drug structure, a purpose of the same, a method of making the same, and a method of using the same to inhibit H. pylori are revealed. The drug carrier includes a negatively charged polymer, chitosan and magnetic particles. The purpose of the drug carrier is to make a drug for inhibiting H. pylori. The drug structure includes a negatively charged polymer, chitosan, magnetic particles and an active ingredient. The method of making the drug structure includes mixing the negatively charged polymer solution, the chitosan solution, the magnetic particles and the active ingredient solution to form an initial solution and allowing ingredients in the initial solution to react and thereby form drug structure particles. The method of using the drug structure to inhibit H pylori includes administering the drug structure to an H. pylori colony. The drug carrier and drug structure demonstrate enhanced therapeutic efficacy.

Abstract: Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder. The nanolipogel includes a lipid bilayer surrounding a hydrogel core, which may optionally include a host molecule, for example, an absorbent such as a cyclodextrin or ion-exchange resin. In preferred embodiments at least one of active agents is an immunosuppressant.

Abstract: A composition and methods of use and preparation are provided. The composition may comprise a magnetic nanoparticle comprising: a passivation layer; and at least one unique entity that is attached to the magnetic nanoparticle. For example, the composition may include a magnetic nanoparticle and an antibody attached to the magnetic nanoparticle. Such magnetic nanoparticle architecture can provide treatment by, and screening of, nanoparticles functionalized with various functional species.

Abstract: Methods for making an osteoimplant are provided. In one embodiment the method includes applying a mechanical force to an aqueous slurry of insoluble collagen fibers to entangle the insoluble collagen fibers so as to form a semi-solid mass of entangled insoluble collagen fibers; and lyophilizing the semi-solid mass of entangled collagen fibers to form the osteoimplant. An osteoimplant containing entangled insoluble collagen fibers is also provided.

Abstract: A granule form e d from a tubular body having an outer surface and an inner surface separated by a matrix, and at least one core defining an opening extending through the tubular body. The outer surface of the matrix is adapted to permit fluid flow into and out of the matrix.

Abstract: The present invention refers to a process for preparing granules or particles comprising afatinib dimaleate, comprising the steps of providing afatinib dimaleate and at least one pharmaceutically acceptable excipient, and preparing granules or particles involving the use of at least one solvent selected from organic solvent and water, wherein all pharmaceutically acceptable excipients used in the process for preparing granules or particles have neutral or acidic properties, and wherein afatinib dimaleate has a solubility of at least 5 mg/ml in said at least one solvent. The present invention further refers to granules or particles comprising afatinib dimaleate that are prepared according to this process. Additionally, the present invention refers to a process for preparing a pharmaceutical composition comprising afatinib dimaleate, as well as to an adsorbate comprising afatinib dimaleate.

Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

Abstract: Described herein is the formulation of immunogenic or vaccine compositions comprising neutral lipid liposome based adjuvants, where the composition is suitable for lyophilisation. In particular, the invention relates to lyophilised forms of such immunogenic or vaccine compositions wherein both the immunogen or vaccine antigen and the adjuvant are present in one and the same vial, as well as to the formulation and manufacture of lyophilised forms of such immunogenic or vaccine composition.

Abstract: Compositions comprising a citrate salt and a calcium carbonate-containing material, articles-of-manufacturing and kits comprising same and uses thereof for inducing blood coagulation and/or for reducing or arresting hemorrhaging, particularly internal hemorrhaging, are disclosed.

Abstract: The presently disclosed subject matter provides compositions, methods, and kits comprising shape memory particles that can be used for delivering a drug and/or treating a disease or disorder in a patient. Specifically, shape changes in the presently disclosed shape memory particles can be used to control drug delivery spatially and/or temporally in a patient. Also provided are compositions, methods, and kits comprising nanoparticles and hypoxia-inducible factor (HIF) inhibitors with or without chemotherapeutic agents for inhibiting HIF activity in a patient and/or treating a hypoxia-associated disease or disorder.

Abstract: Provided herein are antibiotic coated nanoparticles and methods of treating bacterial infection therewith. In particular embodiments, polymyxin B, vancomycin, and/or other antibiotics are linked to nanoparticles (e.g., gold or silica nanoparticles) and utilized for the treatment of bacterial infections.

Abstract: Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided.

Abstract: A broad-based remediation mechanism against MRFs and alternative fecal indicators such as multidrug resistant Pseudomonas aeruginosa, including nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. The current invention relates to mitigation of drug resistant bacteria, for example in hospitals and in food animals, and to the identification. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The invention also relates to the treatment of multi-drug resistant biofilms which mimic in vivo conditions. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRF and alternative resistant strain-induced illnesses without compromising the balance of the beneficial flora in the physiological and ecological microenvironments.

Abstract: Embodiments of the present invention provide a method for treatment of nonvascular body lumen strictures such as benign prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD). The method involves delivering, preferably via drug coated balloon catheters, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and one or more additives.

Abstract: Embodiments of the present invention provide a method for treatment of nonvascular body lumen strictures such as benign prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD). The method involves delivering, preferably via drug coated balloon catheters, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and one or more additives.

Abstract: An orally administrable pharmaceutical preparation containing a protein. More particularly, an orally administrable pharmaceutical preparation including a protein loaded on metal oxide nanoparticles and an amino acid; wherein the amino acid forms an adduct with the protein loaded on metal oxide nanoparticles. An process for the production of the afore-mentioned orally administrable pharmaceutical preparation is also disclosed.

Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells.